An Introduction to Cardiovascular Disease
Cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. CVDs describe a number of conditions affecting the heart and circulation, including coronary heart disease, angina, congenital heart disease, hypertension and stroke. The huge and ever-increasing burden of CVDs on individuals and healthcare systems shows the urgent ongoing need for treatments and preventive measures.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio. If you are looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Cardiovascular Disease Content
Divaka Perera, ACC 2023: Myocardial viability in patients with ischaemic left ventricular dysfunction, the REVIVED-BCIS2 trial
The REVIVED-BCIS2 trial assessed the use of myocardial viability tests in predicting prognosis following revascularization in patients with ischaemic left ventricular dysfunction. In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy’s and St Thomas’ NHS Foundation Trust, London, UK) to discuss the REVIVED-BCIS2 trial, its findings and the impact these results will likely […]
Divaka Perera, ACC 2023: Myocardial viability tests for guiding the ischaemic left ventricular dysfunction treatment paradigm
Ischaemic left ventricular dysfunction is encountered frequently by physicians. Myocardial viability tests are utilised as a prospective tool that enables prediction of a patient’s recoverability. In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy’s and St Thomas’ NHS Foundation Trust, London, UK) to discuss the treatment paradigm for ischaemic left ventricular dysfunction and […]
Low-flow, Low-gradient Severe Aortic Stenosis: A Review
Heart International. 2023;17(1):Online ahead of journal publication
The global prevalence of aortic stenosis (AS) has steadily increased over the past several decades.1 In high-income countries, degenerative calcific aortic valve disease is the primary aetiology for AS, whereas chronic rheumatic valve disease and infective endocarditis remain more common causes worldwide.2 Population-wide trends in developed countries suggest a strong relationship between advanced age and incidence of […]
Strategies for Reducing Vascular and Bleeding Risk for Percutaneous Left Ventricular Assist Device-supported High-risk Percutaneous Coronary Intervention
Heart International. 2022;16(2):105–11 DOI: https://doi.org/10.17925/HI.2022.16.2.105
In recent years, patients undergoing non-emergent percutaneous coronary intervention (PCI) procedures have become increasingly older, with a more significant comorbidity burden and complex coronary disease.1 Many of the patients who undergo elective or urgent PCI are surgical turndown patients, for whom PCI is the only revascularization option.2 For these high-risk patients, more interventionalists are opting for […]
Can Percutaneous Coronary Intervention Revive a Failing Heart?
Heart International. 2022;16(2):72–4 DOI: https://doi.org/10.17925/HI.2022.16.2.72
Percutaneous coronary intervention (PCI) has evolved considerably in both technique and technology since Andreas Grüntzig first intervened on a focal, proximal lesion in the left anterior descending artery in 1977.1 While this has resulted in increasingly complex anatomical subsets being treated, contemporary trials of PCI in patients with stable coronary artery disease (CAD) have continued to […]
Addressing cardiorenal outcomes in CKD and T2D: What are the key considerations for daily practice?
Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D
- Identify the epidemiological and pathophysiological drivers behind the progression of CKD
- Recognize the specific renal and cardiovascular risks associated with CKD and T2D and the therapies available to address them
- Apply the latest clinical guidelines to treating patients with CKD and T2D in daily practice
Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice
Watch cardiology experts discuss how the latest guidelines and treatments are applied to reduce ASCVD risk in patients with dyslipidemias
- Choose appropriate lipid goals for patients with dyslipidemias and at risk of ASCVD, considering the latest guidelines
- Formulate guideline-based and forward-thinking strategies to reduce ASCVD risk in patients with dyslipidemias using appropriate lipid- and lipoprotein-lowering therapies
- Recognize special populations of patients with dyslipidemias and apply important considerations when treating them with lipid- and lipoprotein-lowering therapies
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy
Heart International. 2022;16(2):91–8 DOI: https://doi.org/10.17925/HI.2022.16.2.91
Hypertrophic cardiomyopathy (HCM), along with its more common subgroup, hypertrophic obstructive cardiomyopathy (HOCM), is the most common monogenic cardiovascular disorder, with a prevalence of about 1 in 500,1 and a dominant inheritance pattern, thus clustering in affected families. Patients with HCM often have significant limitations to their exercise capacity, and while there are several underlying pathomechanisms for […]
Zsolt Piroth, TCT 2022: The value of post-PCI FFR and intravascular imaging for cardiovascular failure, a FAME 3 substudy
This FAME 3 substudy aimed to define the value of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) and intravascular imaging for cardiovascular failure. In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the substudy of the FAME 3 trial and the implications for clinical practice. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!